Related Experiment Videos
[Nisoldipine in comparison with long-term nitrates]
B Eber1, M Schumacher, R Zweiker
1Medizinischen Universitätsklinik Graz.
Acta Medica Austriaca
|January 1, 1992
Summary
Nisoldipine, a novel calcium channel blocker, effectively treats coronary artery disease by improving myocardial metabolism and showing vascular selectivity. Its effects on chronic ischemia are comparable to long-acting nitrates, with rare side-effects observed.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary artery disease (CAD) management often involves long-acting nitrates.
- Second-generation dihydropyridine calcium channel blockers offer potential therapeutic advantages.
Purpose of the Study:
- To evaluate nisoldipine as a treatment for coronary artery disease.
- To compare the efficacy and side-effect profile of nisoldipine with long-acting nitrates.
Main Methods:
- The study reviews existing data on nisoldipine's effects in CAD.
- Comparative analysis of nisoldipine's vascular selectivity and inotropic effects.
- Assessment of impact on myocardial metabolism and ischemic episodes.
Main Results:
- Nisoldipine demonstrates high vascular selectivity with minimal negative inotropic effects.
- It exerts a long-lasting positive influence on myocardial metabolism.
- Effects on symptomatic and silent ischemic episodes appear similar to long-acting nitrates, though direct comparative studies are pending.
Conclusions:
- Nisoldipine is a promising second-generation calcium channel blocker for CAD.
- Its favorable profile suggests comparable efficacy to long-acting nitrates with potentially fewer side effects.
- Further direct comparative studies are warranted to confirm its therapeutic role.